School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, UK.
Department of Experimental Immunotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Mol Oncol. 2023 Nov;17(11):2218-2220. doi: 10.1002/1878-0261.13533. Epub 2023 Oct 12.
Immune checkpoint inhibitors (ICIs) are utilised in treating non-small cell lung cancer (NSCLC) by enhancing the immune response against cancer cells. However, they are not effective against cancers with certain genetic alterations. A recent study by Mota et al. focussed on understanding why ALK+ NSCLC cancers are immune cold and making them more receptive to ICIs using a vaccine-based approach. The study highlighted cell-specific differences in the presentation of immunogenic peptides and the location of tumours as factors in the poor immune response. Vaccines based on ALK peptides improved immune response, and when combined with ICIs, this led to a striking improvement in survival in a mouse model of ALK+ NSCLC.
免疫检查点抑制剂（ICIs）通过增强针对癌细胞的免疫反应，被用于治疗非小细胞肺癌（NSCLC）。然而，它们对某些具有特定遗传改变的癌症并不有效。最近由 Mota 等人进行的一项研究集中于了解为什么 ALK+ NSCLC 癌症是免疫冷肿瘤，并通过基于疫苗的方法使它们对 ICI 更敏感。该研究强调了免疫原性肽的呈现和肿瘤位置的细胞特异性差异是免疫反应不佳的因素。基于 ALK 肽的疫苗改善了免疫反应，当与 ICI 联合使用时，这导致 ALK+ NSCLC 的小鼠模型中的生存显著改善。
